Storage-associated physicochemical changes in extracellular vesicles derived from human mesenchymal stromal cells.
Gordiienko I., Petryk N., Kushka I., Nesenyuk O., Lukasevych M., Novikova S.
Laboratory Study, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Front Bioeng Biotechnol (2026)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42597816
- DOI
- 10.3389/fbioe.2026.1829175
Abstract (original English)
Extracellular vesicles (EVs) derived from mesenchymal stromal cells (MSCs) are considered a promising therapeutic tool due to their involvement in intercellular signaling and their ability to carry a wide range of biologically active molecules, including proteins, lipids, and nucleic acids. Standardized protocols for EV manufacturing and evaluation of EV properties under different storage conditions are important to ensure the quality, reproducibility, safety, and therapeutic efficacy of EV-based products. This study evaluated the physicochemical stability of EVs derived from MSCs of various tissue origins under different storage temperatures. MSC populations were isolated from adipose tissue (ADSCs), umbilical cord (UC-MSCs), and dental pulp (DPSCs). The isolated cells met the minimal criteria for defining MSCs. EVs were isolated from conditioned media by differential ultracentrifugation and characterized by nanoparticle tracking analysis (NTA) and ELISA detection of the EV-specific markers CD63, CD81, and TSG101. Total protein concentration was determined using the Pierce BCA colorimetric assay. The physicochemical stability of MSC-derived EVs diluted in Hank's solution was evaluated at predefined intervals during storage at +4 °C to +6 °C, -20 °C, and -80 °C. EV particle concentration and total protein concentration remained stable for at least 14 days at +4 °C to +6 °C and
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.